BNOXBIONOMICS LIMITED/FI

Nasdaq bionomics.com.au


$ 0.55 $ 0.02 (2.64 %)    

Friday, 16-Aug-2024 10:11:10 EDT
QQQ $ 475.24 $ 0.61 (0.13 %)
DIA $ 406.80 $ 0.86 (0.21 %)
SPY $ 554.24 $ 1.24 (0.22 %)
TLT $ 97.41 $ 0.34 (0.35 %)
GLD $ 231.90 $ 5.08 (2.24 %)
$ 0.5902
$ 0.55 x 200
$ 0.62 x 1,000
-- - --
$ 0.50 - $ 6.41
92,958
na
877.47M
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bionomics-receives-notice-of-allowance-for-us-patent-on-substituted-n-heteroaryl-compounds-for-cognitive-function-and-cns-disorders

https://patentcenter.uspto.gov/applications/17441637/ifw/docs

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-to-host-corporate-update-and-discuss-end-of-phase-2-meeting-outcomes-on-the-development-of-bnc210-in-ptsd-on-july-31-2024-at-800-am-et

Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class...

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-files-for-resale-of-up-to-364b-ordinary-shares-by-the-selling-shareholder

- SEC Filing 

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-reveals-detailed-data-from-ptsd-trial-stock-soars

Bionomics' Phase 2b ATTUNE trial on BNC210 for PTSD. Discover statistically significant improvements in symptom severity, c...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION